Rivaroxaban May Be a Suitable Alternative to Low-Molecular Weight Heparin in Cancer-Associated Thrombosis
Among some patients with cancer-associated thrombosis, rivaroxaban may be a viable alternative to low-molecular-weight heparin.
Thromboembolism
Molecular Profiling Can Assess Risk for Myeloproliferative Neoplasms With Splanchnic Vein Thrombosis
Researchers sought to markers that could identify high risk for splanchnic vein thrombosis among patients with MPNs.
Understanding the Association Between COVID-19, Thromboembolism, and Therapeutic Anticoagulation
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Increased Risk of Venous Thromboembolism in Patients With Myelofibrosis
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
Analysis of Thrombotic Events in Patients Receiving Ibrutinib
Researchers found a low incidence of thrombotic events in patients receiving ibrutinib, though some patients still experienced bleeding.
Expert Panel Releases Recommendations on Unmet Clinical Needs With Ph-Negative Myeloproliferative Neoplasms
An overview of the findings of an expert panel that examined the unmet clinical needs for patients with Ph-negative MPNs to assess for risks of thrombosis.
Guideline Update for Venous Thromboembolism Prophylaxis in Patients With Cancer
The American Society of Clinical Oncology released updates to their guidelines for thromboprophylaxis in patients with cancer.
SAVED Tool Improves Assessment of Venous Thromboembolism Risk in Patients With Multiple Myeloma
Retrospective population-based cohort study is used to validate a new risk assessment tool to identify patients receiving immunomodulatory drugs for multiple myeloma who may be at high risk of VTE.
-
Loading...
-
Loading...
Next post in Multiple Myeloma
